Literature DB >> 26000960

Regulation of metastatic ability and drug resistance in pulmonary adenocarcinoma by matrix rigidity via activating c-Met and EGFR.

Chih-Cheng Chang1, Ting-Lieh Hsieh2, Tung-Yu Tiong3, Chi-Hao Hsiao4, Andrea Tung-Qian Ji2, Wei-Tse Hsu2, Oscar K Lee5, Jennifer H Ho6.   

Abstract

Lung fibrosis is a poor prognostic factor for pulmonary adenocarcinoma, and the effect of a rigid microenvironment on cancer behavior is unclear. We cultured A549 cells on matrices of 0.2, 2, and 25 kPa to mimic the rigidities of normal lung parenchyma, progressive fibrotic change, and lung fibrosis, respectively. Lung tissue from patients with pulmonary adenocarcinoma was used to confirm the in vitro findings. Increased matrix rigidity promoted cell proliferation and upregulated the epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (c-Met), and Snail expression in A549 cells. A549 cells became more resistant to the EGFR inhibitor (Erlotinib) and c-Met inhibitor (PHA-665752) when matrix rigidity increased; however, a high concentration of PHA-665752 reversed the rigidity-induced morphological pleomorphism. In human lung tissue, expression of type I collagen was more consistent with clinical fibrosis than the expression of alpha-smooth muscle antibody was. c-Met- and Snail-expressing tumor cells, rather than EGFR-experssing cells, were localized with lung parenchyma rich in type I collagen. Our findings suggest that c-Met causes the rigidity-induced biophysical reaction in pulmonary adenocarcinoma. Treatment targeting both EGFR and c-Met should be considered for patients with lung fibrosis and who are abundant type I collagen expression in the tumor mass.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adenocarcinoma; Drug resistance; Epidermal growth factor receptor; Lung fibrosis; Matrix rigidity; c-Met

Mesh:

Substances:

Year:  2015        PMID: 26000960     DOI: 10.1016/j.biomaterials.2015.04.058

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  8 in total

Review 1.  Materials-driven approaches to understand extrinsic drug resistance in cancer.

Authors:  Justin R Pritchard; Michael J Lee; Shelly R Peyton
Journal:  Soft Matter       Date:  2022-05-11       Impact factor: 4.046

2.  LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma.

Authors:  Junbin Wang; Jin Gao; Qinnan Chen; Weiyan Zou; Fen Yang; Chenchen Wei; Zhaoxia Wang
Journal:  Onco Targets Ther       Date:  2020-09-22       Impact factor: 4.147

Review 3.  Biophysics Role and Biomimetic Culture Systems of ECM Stiffness in Cancer EMT.

Authors:  Hao Tian; Hanhan Shi; Jie Yu; Shengfang Ge; Jing Ruan
Journal:  Glob Chall       Date:  2022-03-20

4.  A biomaterial screening approach reveals microenvironmental mechanisms of drug resistance.

Authors:  Alyssa D Schwartz; Lauren E Barney; Lauren E Jansen; Thuy V Nguyen; Christopher L Hall; Aaron S Meyer; Shelly R Peyton
Journal:  Integr Biol (Camb)       Date:  2017-12-11       Impact factor: 2.192

5.  Transcriptome sequencing analysis of primary fibroblasts: a new insight into postoperative abdominal adhesion.

Authors:  Fuling Wu; Yilei Li; Qin Yang; Canmao Wang; Lianbing Hou; Wenqin Liu; Chuqi Hou
Journal:  Surg Today       Date:  2021-06-12       Impact factor: 2.549

6.  Optimization Of Cancer Treatment Through Overcoming Drug Resistance.

Authors:  Yahya I Elshimali; Yong Wu; Hussein Khaddour; Yanyuan Wu; Daniela Gradinaru; Hema Sukhija; Seyung S Chung; Jaydutt V Vadgama
Journal:  J Cancer Res Oncobiol       Date:  2018-02-27

Review 7.  The role of collagen in cancer: from bench to bedside.

Authors:  Shuaishuai Xu; Huaxiang Xu; Wenquan Wang; Shuo Li; Hao Li; Tianjiao Li; Wuhu Zhang; Xianjun Yu; Liang Liu
Journal:  J Transl Med       Date:  2019-09-14       Impact factor: 5.531

8.  Co-delivery of sorafenib and crizotinib encapsulated with polymeric nanoparticles for the treatment of in vivo lung cancer animal model.

Authors:  Tian Zhong; Xingren Liu; Hongmin Li; Jing Zhang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.